Context · Frontier AI · sweep Tuesday, November 17, 2026
Generative models of peptides and antibodies with laboratory validation
The computational generation of therapeutic peptides and antibodies migrates from similarity benchmarks to metrics of functional binding confirmed in the laboratory, with industry reports claiming success rates of 18/19 in de novo projects. The bottleneck shifts from algorithmic design to experimental validation and synthesis capacity, which couples the AI frontier with physical biomanufacturing resources.
Title, thesis and gravity assessment written by an AI model, without prior human review.
Gravity60/100 · Context
Why this gravity
El cluster combina tres preprints arXiv (benchmarks de binding funcional y generación de péptidos) con un technical report autopublicado de MoleculeMind que reclama binders confirmados en laboratorio en 18/19 proyectos, incluidos seis targets GPCR; la señal es materialmente distinta a los benchmarks de similitud, pero el dato central proviene de una sola fuente corporativa sin replicación independiente ni peer review.
- Coverage
- 2 feeds · 2 independent publisher groups (corroborated)
- Cross verticals
- Frontier AI, Lifespan & Healthspan, Energy & Materials
- Gravity vs. the previous edition
- +38 (22 → 60)
coverage, not accuracy
Lead source
Pepti-drift: Scalable Safe-Active Peptide Generation Without Inference-Time Guidance · arXiv CS.AI / Takashi Fujiwara, Hikaru Shindo, Kaushalya Madhawa, Jun Jin Choong, Shuan Chen, Yuna Oikawa, Yiming Zhang, Gyubok Lee, Keisuke OzawaMore: PandaDaily
Timeline · Madrid time
- 06:00
- 03:01
- 05:00
- 06:00
ShareWhatsApp
Related stories
- 0Persistent memory in vision-language-action models for robotic navigation and manipulation
- 80AI agents discovering and patching critical vulnerabilities in open infrastructure
- 80DeepSeek expansion in agents, APIs and inference infrastructure
- 80Moonshot's Kimi K3.1 Pro and open weights in frontier models
- 72OpenAI offensive cybersecurity models and deployment in government clouds